SEMA5A and neoplasm: Consistent with this is a recent study that reports the presence a novel missense mutation in plexin-B3 in human pancreatic ductal adenocarcinomas, which prevents interaction with its ligand Sema5A, hence impairing their signaling and contributing to tumor progression [87].